JP2013505286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505286A5 JP2013505286A5 JP2012530326A JP2012530326A JP2013505286A5 JP 2013505286 A5 JP2013505286 A5 JP 2013505286A5 JP 2012530326 A JP2012530326 A JP 2012530326A JP 2012530326 A JP2012530326 A JP 2012530326A JP 2013505286 A5 JP2013505286 A5 JP 2013505286A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- inflammatory
- fragment
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 9
- 230000004927 fusion Effects 0.000 claims 9
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims 8
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims 4
- 230000014508 negative regulation of coagulation Effects 0.000 claims 4
- 206010053567 Coagulopathies Diseases 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 208000015294 blood coagulation disease Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 102000055046 tissue-factor-pathway inhibitor 2 Human genes 0.000 claims 3
- 108010016054 tissue-factor-pathway inhibitor 2 Proteins 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 206010051548 Burn infection Diseases 0.000 claims 1
- 206010007882 Cellulitis Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 201000000297 Erysipelas Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010020608 Hypercoagulation Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000007117 Oral Ulcer Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010067268 Post procedural infection Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 230000003027 hypercoagulation Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010033072 otitis externa Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0916578.8A GB0916578D0 (en) | 2009-09-22 | 2009-09-22 | Polypeptides and uses thereof |
| GB0916578.8 | 2009-09-22 | ||
| PCT/GB2010/001781 WO2011036445A2 (en) | 2009-09-22 | 2010-09-22 | Polypeptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505286A JP2013505286A (ja) | 2013-02-14 |
| JP2013505286A5 true JP2013505286A5 (enExample) | 2013-10-24 |
Family
ID=41278086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012530325A Pending JP2013505030A (ja) | 2009-09-22 | 2010-09-21 | 抗炎症及び抗凝固活性を有するヘパリンコファクターｉｉ断片 |
| JP2012530326A Abandoned JP2013505286A (ja) | 2009-09-22 | 2010-09-22 | ポリペプチド及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012530325A Pending JP2013505030A (ja) | 2009-09-22 | 2010-09-21 | 抗炎症及び抗凝固活性を有するヘパリンコファクターｉｉ断片 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9169315B2 (enExample) |
| EP (2) | EP2480244A1 (enExample) |
| JP (2) | JP2013505030A (enExample) |
| CN (2) | CN102655874B (enExample) |
| AU (2) | AU2010299630A1 (enExample) |
| BR (2) | BR112012006502A2 (enExample) |
| CA (2) | CA2774288A1 (enExample) |
| EA (1) | EA201200515A1 (enExample) |
| GB (1) | GB0916578D0 (enExample) |
| IN (2) | IN2012DN02981A (enExample) |
| MX (1) | MX2012003425A (enExample) |
| WO (2) | WO2011036444A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140296146A1 (en) * | 2011-08-23 | 2014-10-02 | Synapse B.V. | Thermostable Inhibitors of Activation of the Blood Clotting System Through Contact with Foreign Surfaces |
| RU2476231C1 (ru) * | 2011-10-11 | 2013-02-27 | Федеральное государственное бюджетное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации | Способ купирования некроза краев кожи послеоперационной раны после эндопротезирования голеностопного сустава |
| GB2500184A (en) * | 2012-03-12 | 2013-09-18 | Ximmune Ab | Polypeptide derived from helix A of heparin cofactor II |
| CN104292309B (zh) * | 2014-09-29 | 2017-04-12 | 广西中医药大学 | 一种小分子多肽 |
| JPWO2016104436A1 (ja) * | 2014-12-22 | 2017-10-26 | 国立大学法人 岡山大学 | サイトカインストーム抑制剤 |
| RU2606836C2 (ru) * | 2015-03-12 | 2017-01-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Антикоагулянтный, антитромбоцитарный и фибриндеполимеризационный комплекс на основе гепарина, способ его получения и применение |
| RU2610433C1 (ru) * | 2016-02-17 | 2017-02-10 | Людмила Анисимовна Ляпина | Антикоагулянт |
| CN107875372A (zh) * | 2017-12-20 | 2018-04-06 | 辽宁师范大学 | 重组肽rLj‑112在制备协同肝素抗凝药物中的应用 |
| CN108338163A (zh) * | 2018-03-28 | 2018-07-31 | 陈太师 | 一种持效型杀菌灭藻剂的制备方法 |
| US20210198317A1 (en) * | 2018-05-31 | 2021-07-01 | National University Corporation Okayama University | Reactive oxygen production inhibitor and/or scavenging promoter |
| CN112512547A (zh) * | 2018-06-28 | 2021-03-16 | 国立大学法人冈山大学 | 嗜中性粒细胞吞噬能力增强剂 |
| JP7518061B2 (ja) * | 2018-08-16 | 2024-07-17 | エフ． ホフマン－ラ ロシュ アーゲー | 心房細動および抗凝固療法の評価における循環ｔｆｐｉ－２（組織因子経路阻害剤２） |
| CN109432513B (zh) * | 2018-12-12 | 2021-03-23 | 中国医科大学 | 一种具有抗血栓再形成功能的生物材料及其制备方法 |
| US11904000B2 (en) | 2019-05-06 | 2024-02-20 | Brown University | Compositions and methods to enhance cutaneous wound healing |
| JP2023526880A (ja) * | 2020-05-26 | 2023-06-26 | ウニヴェルシテーツメディツィン・デア・ヨハネス・グーテンベルク－ウニヴェルシテート・マインツ | コロナウイルス感染症および関連する凝固障害を処置するための方法および組成物 |
| CN114113601A (zh) * | 2020-08-25 | 2022-03-01 | 张曼 | 尿液肝素辅因子ii及其多肽片段在烧伤中的应用 |
| CN117534731B (zh) * | 2021-09-24 | 2024-10-29 | 深圳市海伦海生物科技有限公司 | 一种抗凝血肽及其在抗凝血产品上的应用 |
| CN114886116B (zh) * | 2022-03-18 | 2023-11-21 | 广东丸美生物技术股份有限公司 | 一种调理育龄女性健康的组合物及其制备方法和饮料及应用 |
| US20250353898A1 (en) * | 2022-04-29 | 2025-11-20 | Serpin Pharma, Llc | Serpin peptide derivatives and methods of using the same |
| CN116510074A (zh) * | 2023-03-13 | 2023-08-01 | 西南交通大学 | 一种胆碱磷酸功能化可植入钛支架的制备方法 |
| CN116836233B (zh) * | 2023-08-31 | 2023-11-14 | 中国农业大学 | 抗炎活性多肽及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US5102995A (en) * | 1989-10-20 | 1992-04-07 | Washington University | Dna encoding modified heparin cofactor ii |
| US5118793A (en) * | 1989-10-20 | 1992-06-02 | Washington University | Modified heparin cofactor II |
| US5643872A (en) | 1989-10-23 | 1997-07-01 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
| AU1873092A (en) | 1991-04-09 | 1992-11-17 | Brigham And Women's Hospital | Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques |
| US6008058A (en) | 1993-06-18 | 1999-12-28 | University Of Louisville | Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis |
| US5589359A (en) * | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
| US5712247A (en) * | 1995-02-21 | 1998-01-27 | University Of North Carolina | Use of lactoferrin to modulate and/or neutralize heparin activity |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| JPH09176040A (ja) * | 1995-12-27 | 1997-07-08 | Green Cross Corp:The | ヘパリンコファクターｉｉの医薬用途 |
| US6946439B2 (en) * | 1997-02-06 | 2005-09-20 | Entre Med, Inc. | Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments |
| AU2878199A (en) * | 1998-02-27 | 1999-09-15 | University Of North Carolina At Chapel Hill, The | Mutant heparin cofactor ii |
| AU1410801A (en) * | 1999-11-17 | 2001-05-30 | Compugen Ltd. | Variants of alternative splicing |
| CA2454418A1 (en) * | 2001-07-20 | 2003-01-30 | Eidgenoessische Technische Hochschule Zurich (Ethz) | Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| GB0131112D0 (en) | 2001-12-31 | 2002-02-13 | Univ London Pharmacy | Block copolymers |
| CA2487901A1 (en) * | 2002-05-31 | 2003-12-11 | University Of Utah Research Foundation | Variants of antithrombin iii |
| AU2003294401C1 (en) * | 2002-11-22 | 2008-09-18 | Ansun Biopharma, Inc. | Broad spectrum anti-viral therapeutics and prophylaxis |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| WO2005015206A2 (en) | 2003-08-08 | 2005-02-17 | Genova Ltd. | Secreted polypeptide species associated with cardiovascular disorders |
| MXPA06010587A (es) * | 2004-03-17 | 2007-03-29 | Chiron Corp | Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi). |
| US20050261241A1 (en) * | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| KR20080017021A (ko) * | 2005-05-06 | 2008-02-25 | 노바티스 아게 | 중증 박테리아 감염을 치료하기 위한 ｔｆｐｉ의 용도 |
| WO2007014199A2 (en) * | 2005-07-22 | 2007-02-01 | Novartis Ag | Tfpi fragments as anti-microbial agents |
| PT1976985E (pt) * | 2005-12-29 | 2013-10-24 | Univ California | Métodos e composições relacionados com o domínio 1 mutante de kunitz do tfpi-2 |
| EP1981519B1 (en) * | 2005-12-29 | 2017-12-27 | Dyax Corp. | Protease inhibition |
| JP2009526046A (ja) * | 2006-02-10 | 2009-07-16 | デルマゲン アクティエボラーグ | 新規分子 |
| RU2571931C2 (ru) * | 2007-04-13 | 2015-12-27 | Каталист Биосайенсис, Инк. | Полипептиды на основе модифицированного фактора vii и их применение |
| RU2010102865A (ru) * | 2007-07-24 | 2011-08-27 | НексБио, Инк. (US) | Технология изготовления микрочастиц |
-
2009
- 2009-09-22 GB GBGB0916578.8A patent/GB0916578D0/en not_active Ceased
-
2010
- 2010-09-21 BR BR112012006502A patent/BR112012006502A2/pt not_active IP Right Cessation
- 2010-09-21 JP JP2012530325A patent/JP2013505030A/ja active Pending
- 2010-09-21 CA CA2774288A patent/CA2774288A1/en not_active Abandoned
- 2010-09-21 WO PCT/GB2010/001780 patent/WO2011036444A1/en not_active Ceased
- 2010-09-21 EP EP10777056A patent/EP2480244A1/en not_active Withdrawn
- 2010-09-21 EA EA201200515A patent/EA201200515A1/ru unknown
- 2010-09-21 MX MX2012003425A patent/MX2012003425A/es not_active Application Discontinuation
- 2010-09-21 US US13/497,006 patent/US9169315B2/en not_active Expired - Fee Related
- 2010-09-21 AU AU2010299630A patent/AU2010299630A1/en not_active Abandoned
- 2010-09-21 CN CN201080052695.8A patent/CN102655874B/zh not_active Expired - Fee Related
- 2010-09-21 IN IN2981DEN2012 patent/IN2012DN02981A/en unknown
- 2010-09-22 CN CN2010800527096A patent/CN102639556A/zh active Pending
- 2010-09-22 WO PCT/GB2010/001781 patent/WO2011036445A2/en not_active Ceased
- 2010-09-22 US US13/497,195 patent/US20120189673A1/en not_active Abandoned
- 2010-09-22 BR BR112012006501A patent/BR112012006501A8/pt not_active IP Right Cessation
- 2010-09-22 JP JP2012530326A patent/JP2013505286A/ja not_active Abandoned
- 2010-09-22 CA CA2774296A patent/CA2774296A1/en not_active Abandoned
- 2010-09-22 AU AU2010299631A patent/AU2010299631A1/en not_active Abandoned
- 2010-09-22 EP EP10777057A patent/EP2480564A2/en not_active Withdrawn
- 2010-09-22 IN IN3368DEN2012 patent/IN2012DN03368A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505030A5 (enExample) | ||
| CN102655874B (zh) | 具有抗炎和抗凝活性的肝素辅因子ii片段 | |
| JP5330230B2 (ja) | 改良型抗菌ペプチド | |
| Høiby | Diffuse panbronchiolitis and cystic fibrosis: East meets West | |
| JP2009526046A (ja) | 新規分子 | |
| JP2009526045A (ja) | 新規抗菌ペプチド及びその使用 | |
| ES2395206T3 (es) | Uso de péptidos antimicrobianos con actividad de unión a heparina | |
| JP2008501316A5 (enExample) | ||
| JP2013529916A5 (enExample) | ||
| JP4898698B2 (ja) | 新規抗菌性ペプチド | |
| CA2657338C (en) | Anti-inflammatory and antiallergic cyclic peptides | |
| JP2009528293A5 (enExample) | ||
| JP2024539138A (ja) | 多価効果を持つペプチド | |
| CN116635056A (zh) | 长效脱氧核糖核酸酶 | |
| Manolov et al. | Moraxella-dependent α1-antichymotrypsin neutralization: A unique virulence mechanism | |
| ES2760990T3 (es) | Fragmento de lactoferrina para la utilización como agente antibacteriano y antiviral | |
| GB2500184A (en) | Polypeptide derived from helix A of heparin cofactor II | |
| Sapey et al. | The importance of chronic bronchitis in chronic obstructive pulmonary disease | |
| Dymek et al. | Dual AMCase/CHIT1 Inhibitor OAT-889 Reverses Pulmonary Inflammation and Airway Remodeling in Two Mice Models of Airway Inflammation | |
| JP2009502810A (ja) | 補体系と相互作用する抗微生物剤 | |
| CN102886054A (zh) | 一种抑制细菌信号转导系统PhoQ组氨酸激酶活性的制剂 | |
| CN102886055B (zh) | 一种细菌PhoQ组氨酸激酶抑制剂 | |
| Williamson | The Role of Competitive Glycosaminoglycan Binding in Determining the Inflammatory Profile of the Cystic Fibrosis Airway | |
| Hartwig et al. | The effector protein ExoY secreted by Pseudomonas aeruginosa augments the inflammatory reaction in the respiratory tract of mice | |
| Tonsils | Expression and Localization of Human Defensins in |